XTX301 in Patients With Advanced Solid Tumors

ClinicalTrials.gov ID: NCT05684965

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT05684965. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX301 as monotherapy in patients with advanced solid tumors.

Study identification

NCT ID: NCT05684965
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Xilio Development, Inc.; Industry
Enrollment: 358 participants

Conditions and interventions

Conditions

Advanced Solid Tumor

Interventions

XTX301 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 11, 2023 (Actual)
Primary completion: Sep 2028 (Estimated)
Completion: Sep 2028 (Estimated)
Last update posted: Jun 23, 2026

2023 – 2028

United States locations

U.S. sites: 12
U.S. states: 9
U.S. cities: 12

Facility	City	State	ZIP	Site status
University of California, Davis Comprehensive Cancer Center	Sacramento	California	95817	Recruiting
Yale Cancer Center	New Haven	Connecticut	06510	Recruiting
HealthPartners Frauenshuh Cancer center	Saint Louis Park	Minnesota	55426	Recruiting
Washington University School of Medicine	St Louis	Missouri	63110	Recruiting
Hackensack University Medical Center	Hackensack	New Jersey	07601	Recruiting
The Gabrail Pharmacology Phase 1 Research Center	Canton	Ohio	44718	Recruiting
University Hospital Cleveland Medical Center	Cleveland	Ohio	44106	Recruiting
The Ohio State University Wexner Medical Center	Columbus	Ohio	43221	Recruiting
University of Pittsburgh Medical Center-Hillman Cancer Center	Pittsburgh	Pennsylvania	15232	Recruiting
Tranquil Clinical Research	Webster	Texas	77598	Completed
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting
Sheboygan Cancer & Blood Specialists	Sheboygan	Wisconsin	53081	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05684965, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 23, 2026 · Synced Nov 13, 2026